ASTC on Nasdaq

Astrotech Corporation

Logo: Astrotech, Public domain, via Wikimedia Commons5

Technology incubator based in Texas, US

Astrotech Corporation, formerly Spacehab Inc., is a technology incubator headquartered in Austin, Texas. Astrotech uses technology sourced internally and from research institutions, government laboratories, and universities to fund, manage and sell start-up companies. Astrotech Corporation's subsidiaries provide commercial products and services to NASA, the U.S. Department of Defense, national space agencies, and global commercial customers.3 It was founded by Bob Citron.1 Its shares trade on Nasdaq under the symbol ASTC.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$913.0KRevenue, fiscal 20266
-$14.4MNet income, fiscal 20266
1984Founded1

Compare with SCIENTIFIC INDUSTRIES INC, Lifeloc Technologies, Inc or Accelerate Diagnostics, or pick any stock.

  • TickerASTC on Nasdaq1
  • Industryaerospace industry1
  • HeadquartersAustin1
  • Websitewww.astrotechcorp.com
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address2105 Donley Dr. Suite 100, Austin, Tx 787587
  • Filer categoryNon-accelerated filer, Smaller reporting company7
  • LEI984500DA81B780C7D5584
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressCORPORATION TRUST CENTER, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 66756074

Astrotech Corporation, formerly Spacehab Inc., is a technology incubator headquartered in Austin, Texas. Astrotech uses technology sourced internally and from research institutions, government laboratories, and universities to fund, manage and sell start-up companies. Astrotech Corporation's subsidiaries provide commercial products and services to NASA, the U.S. Department of Defense, national space agencies, and global commercial customers.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

23.8%Gross margin6
-1548.5%Operating margin6
-1580.2%Net margin6
-8.7%Revenue growth, 20266
-89.2%Return on equity6
-$14.3MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue5¢$696.0K
  • Research and development43¢$6.5M
  • Selling, general and admin52¢$7.9M
  • Income tax0¢$4.0K

Out of $913.0K in revenue.6 The company lost money this year.

Financial statements

Revenue1011121314156$913.0K in 2026+619% since 2019
0$500.0K$1.0M$1.5M$2.0M2019: $127.0K$127.0K20192020: $488.0K$488.0K2020+284%2021: $334.0K$334.0K2021−32%2022: $869.0K$869.0K2022+160%2023: $750.0K$750.0K2023−14%2024: $1.7M$1.7M2024+127%2025: $1.0M$1.0M2025−41%2026: $913.0K$913.0K2026−9%
Gross profit1011121314156$217.0K in 2026+486% since 2019
0$200.0K$400.0K$600.0K$800.0K2019: $37.0K$37.0K20192020: $39.0K$39.0K2020+5%2021: $36.0K$36.0K2021−8%2022: $192.0K$192.0K2022+433%2023: $306.0K$306.0K2023+59%2024: $751.0K$751.0K2024+145%2025: $475.0K$475.0K2025−37%2026: $217.0K$217.0K2026−54%
Operating income1011121314156-$14.1M in 2026+68% since 2019
-$15.0M-$10.0M-$5.0M02019: -$8.4M-$8.4M20192020: -$8.1M-$8.1M2020−4%2021: -$7.9M-$7.9M2021−3%2022: -$8.6M-$8.6M2022+9%2023: -$11.1M-$11.1M2023+29%2024: -$13.3M-$13.3M2024+20%2025: -$14.7M-$14.7M2025+11%2026: -$14.1M-$14.1M2026−4%
Net income1011121314156-$14.4M in 2026+91% since 2019
-$15.0M-$10.0M-$5.0M02019: -$7.5M-$7.5M20192020: -$8.3M-$8.3M2020+10%2021: -$7.6M-$7.6M2021−9%2022: -$8.3M-$8.3M2022+10%2023: -$9.6M-$9.6M2023+16%2024: -$11.7M-$11.7M2024+21%2025: -$13.8M-$13.8M2025+19%2026: -$14.4M-$14.4M2026+4%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2026-06-302025-06-302024-06-30
Revenue$913.0K$1.0M
Cost of revenue$696.0K$574.0K
Gross profit$217.0K$475.0K
Selling, general and administrative$7.9M$7.1M
Research and development$6.5M$8.1M
Total operating expenses$14.4M$15.2M
Loss from operations-$14.1M-$14.7M
Interest and dividend income$471.0K$1.1M
Realized loss-$543.0K-$5.0K
Other income and expense, net-$213.0K-$203.0K
Total other income(expense)-$285.0K$886.0K
Loss from operations before income taxes-$14.4M-$13.8M-$11.7M
Income tax benefit /(expense)-$4.0K-$2.0K
Net loss-$14.4M-$13.8M
Basic and diluted (in shares)1.7M shares1.7M shares
Net loss per common share (in dollars per share)-$8.49-$8.32
Net unrealized gain$548.0K$313.0K
Total comprehensive loss-$13.9M-$13.5M

Compare Astrotech Corporation with another company

Corporate structure

Astrotech Corporation sits at the top of its group. 13 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Astrotech Corporation

  • Astrotech Corporation Wilmington, Delaware, United States
    • 1) Astrogenetix, Inc. Subsidiary · Delaware, United States
    • 10) Pro-Control, Inc. Subsidiary · Delaware, United States
    • 11) En-Scan, Inc. Subsidiary · Delaware, United States
    • 12) Lunar Power and Light Corporation Subsidiary · Delaware, United States
    • 2) 1st Detect Corporation Subsidiary · Delaware, United States
    • 3) Agriculture Technology Corporation Subsidiary · Delaware, United States
    • 4) Medikinetix, Inc. Subsidiary · Delaware, United States
    • 5) Astrotech Technologies, Inc. Subsidiary · Delaware, United States
    • 6) BreathTech Corporation Subsidiary · Delaware, United States
    • 7) AgLAB Inc. Subsidiary · Delaware, United States
    • 8) Cargo Security Center International, Inc. Subsidiary · Delaware, United States
    • 9) AgLAB Remediation Company, LLC Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Astrotech Corporation reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$5.2M6 Jun 30, 2026$4.6M6 Jun 30, 2025+11.8%
Accumulated depreciation$2.8M6 Jun 30, 2026$2.2M6 Jun 30, 2025+25.1%
Property and equipment, net$2.4M6 Jun 30, 2026$2.4M6 Jun 30, 2025−0.5%
Finance-lease assets$108.0K6 Jun 30, 2026$79.0K6 Jun 30, 2025+36.7%
Operating-lease assets (leased space)$1.8M6 Jun 30, 2026$2.2M6 Jun 30, 2025−17.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$8.4M6 Jun 30, 2026$3.1M6 Jun 30, 2025+170.5%
Marketable securities, current$2.9M6 Jun 30, 2026$15.1M6 Jun 30, 2025−80.5%
Marketable securities, non-current$06 Jun 30, 2026$06 Jun 30, 2025
Debt securities available for sale$2.9M6 Jun 30, 2026$15.1M6 Jun 30, 2025−80.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$50.0K6 Jun 30, 2026$48.0K6 Jun 30, 2025+4.2%

Inventory

ItemLatestA year beforeChange
Raw materials$2.9M6 Jun 30, 2026$2.2M6 Jun 30, 2025+33.4%
Work in process$9.0K6 Jun 30, 2026$425.0K6 Jun 30, 2025−97.9%
Finished goods$1.2M6 Jun 30, 2026$310.0K6 Jun 30, 2025+280.3%

Properties, in its own words

On January 29, 2025, we entered into a new lease agreement for a facility of approximately 17,628 square feet in Austin, Texas (the “Metric Facility”) for a term of 89-months, which term commenced on July 1, 2025. The Metric Facility is intended to support and encompass all Austin-based functions. Our total contractual base rent obligation for the Metric Facility is approximately $3.0 million, less a tenant allowance of $312.5 thousand, resulting in a net lease commitment of approximately $2.7 million.

Our equipment lease is for a device used in our research and development efforts.

The rest of Item 2

We believe that our current facility and equipment are well maintained and in good condition. The facility and equipment are adequate for our present needs.

Item 2 of the 10-K filed Sep 25, 2026.19

The story

Founded by Bob Citron in 1984.1

Spacehab (1984–2009)

Spacehab was founded in 1984 by Bob Citron with the help and support of CSP Associates from Cambridge, Massachusetts. The team from CSP Associates included founder David W. Lippy along with his partners Brad Meslin and Marc Oderman. It was one of CSP's consultants, Dr. David Williamson who conceived of the idea to increase the cargo space on the Shuttles as the primary focus of the Spacehab mission. Early venture capital was supplied by Al Zesiger of BEA Associates in New York City as well as Dr. Shelley Harrison also from New York. CSP Associates and its venture contacts were responsible for raising most of the early seed money to get the company off the ground and funded. Throughout its more than 20-year history, Spacehab has contracted over $1 billion dollars in total sales.

Spacehab hardware for Space Shuttle missions

Spacehab hardware consisted of:

Integrated Cargo Carrier (ICC), unpressurized

External Stowage Platform (ESP-2 and ESP-3), an ICC variant

Logistics Single Module (LSM) and Logistics Double Module (LDM)

Single Module (SM) and Research Double Module (RDM), pressurized

The Spacehab hardware was designed to be nestled inside the cargo bay of the Space Shuttles and flew on 22 Space Shuttle missions, including seven to the Russian space station Mir and eight to the International Space Station (ISS). The Single Module flew on seven missions, and the Research Double Module flew only on the ill-fated Columbia STS-107 mission, in which it was destroyed.

The inaugural flight of Spacehab's research double module, which launched January 2003 on STS-107, ended when the Space Shuttle Columbia broke up during re-entry. In February 2003 Spacehab received $17.7 million from its commercial insurance policy. In January 2004, Spacehab filed a formal claim against NASA for the amount of $87.7 million for the loss caused by the Columbia disaster and in October 2004 NASA paid the company $8.2 million. In February 2007, Spacehab dropped all litigation against NASA.

Read the full text

Spacehab's ICC hardware was further developed into the External Stowage Platform (ESP-2 and ESP-1), which are permanently deployed on the ISS. The ESP-2 is attached to the International Space Station's airlock, providing the only permanent, commercial "spare parts" facility for the ISS crew. ESP-3 was deployed during Space Shuttle mission STS-118, on August 8, 2007.

Flights

Legend:

ESP - External Stowage Platform

ICC - Integrated Cargo Carrier

LDM - Logistics Double Module

LSM - Logistics Single Module

SM - Single Module

RDM - Research Double Module

Astrotech Corporation (2009–present)

The Company changed its name to Astrotech Corporation in 2009 to align the corporate name with the company's core business offering, Astrotech Space Operation. ASO provides all support necessary for government and commercial customers to successfully process their satellite hardware for launch–including planning; construction and use of unique equipment and facilities; and spacecraft checkout, encapsulation, fueling, and transport. Astrotech Corporation management sold ASO, its state-of-the-art satellite servicing operations, to Lockheed Martin in August 2014.

Chemical detection and analysis

1st Detect, an Astrotech subsidiary, develops, manufactures, and sells mass spectrometers that can be used in explosive and chemical warfare detection for the Department of Homeland Security and the military. 1st Detect's miniature mass spectrometer technology was sourced from Oak Ridge National Laboratory's chemical analyzer research.

The company Astrotech Corporation (NASDAQ: ASTC) announced that its Astrotech Technologies, Inc. subsidiary had entered into an agreement with Sanmina Corporation to manufacture its mass spectrometry products. As part of the relationship, Sanmina will manufacture 1st Detect's TRACER 1000. They also agreed to manufacture AgLAB's AgLAB-1000 and BreathTech's BreathTest-1000 once those products are released.

Film restoration, correction, and enhancement

Astral Images sells conversion of film to digital images, using defect removal and color correction software, and post processing services, providing economically feasible conversion of television and feature 35mm and 16mm films to the new 4K ultra-high definition (UHD), high-dynamic range (HDR) format necessary for the new generation of digital distribution. Astral Images' core technology is sourced from decades of image research from the laboratories of IBM and Kodak combined with classified satellite technology from government laboratories.

Vaccine development

Sourced from NASA's extensive microgravity research, Astrogenetix is applying a fast-track on-orbit discovery platform using the International Space Station to develop vaccines and other therapeutics.

Space operations

Prior to the 2014 Lockheed Martin acquisition, Astrotech provided both the government and commercial space markets with satellite processing services through its Astrotech Space Operations (ASO) subsidiary located in Titusville, Florida, three miles (5 km) from the Kennedy Space Center. It has more than 150,000 square feet (14,000 m2) of clean room processing space, and services payloads, or satellites, for United Launch Alliance's Atlas and Delta rocket families, Orbital Sciences' Taurus and Pegasus, and SpaceX's Falcon 9 launch vehicles. Astrotech owned and operated processing facilities located on Vandenberg Space Force Base at the Western Range in California. Also in California, ASO provided payload processing and facilities management support for the ocean-going Sea Launch program at the Home Port Facilities in Long Beach.

ARCTUS

On December 10, 2007, Spacehab released details about its planned Advanced Research and Conventional Technology Utilization Spacecraft designed to deliver cargo to, and return cargo from, the International Space Station. The project was later shelved.

From Wikipedia’s article on Astrotech Corporation, shared under CC BY-SA 4.0.8

Leadership

Who has led Astrotech Corporation, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (23)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • 1) Astrogenetix, Inc. Delaware9
  • 10) Pro-Control, Inc. Delaware9
  • 11) En-Scan, Inc. Delaware9
  • 12) Lunar Power and Light Corporation Delaware9
  • 2) 1st Detect Corporation Delaware9
  • 3) Agriculture Technology Corporation Delaware9
  • 4) Medikinetix, Inc. Delaware9
  • 5) Astrotech Technologies, Inc. Delaware9
  • 6) BreathTech Corporation Delaware9
  • 7) AgLAB Inc. Delaware9
  • 8) Cargo Security Center International, Inc. Delaware9
  • 9) AgLAB Remediation Company, LLC Delaware9

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • ASTROTECH Corp \WA\Mar 11, 2009 to Aug 24, 20157
  • SPACEHAB INC \WA\May 9, 1996 to Feb 25, 20097

Timeline

  1. Sep 25, 20268-K Results of operations55
  2. Aug 19, 20268-K Other events56
  3. Jul 22, 20268-K Executive or director change; Regulation FD disclosure57
  4. Jun 16, 20268-K Other events58
  5. Jun 3, 20268-K Entered a material agreement59
  6. May 13, 20268-K Results of operations60
  7. Feb 13, 20268-K Results of operations61
  8. Dec 17, 20258-K Entered a material agreement; Change to shareholders' rights; Shareholder vote62
  9. Nov 13, 20258-K Results of operations63
  10. Nov 12, 20258-K Executive or director change64
  11. Oct 31, 20258-K Executive or director change; Regulation FD disclosure65
  12. Oct 23, 20258-K Executive or director change66
  13. Dec 10, 2014New chief executive Bob Kibler becomes CEO20
  14. Jul 22, 2008New chief executive Thomas Boone Pickens Iii. becomes CEO22
  15. Jul 22, 2008New chief executive Lance W. Lord becomes CEO21
  16. Aug 10, 2006New chief executive Michael E. Kearney becomes CEO23
  17. 1984Founded Founded1

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202667

When it reported results

  1. Sep 25, 2026Reported quarterly or annual results55
  2. May 13, 2026Reported quarterly or annual results60
  3. Feb 13, 2026Reported quarterly or annual results61
  4. Nov 13, 2025Reported quarterly or annual results63
  5. Sep 25, 2025Reported quarterly or annual results68
  6. May 13, 2025Reported quarterly or annual results69
  7. Feb 14, 2025Reported quarterly or annual results70
  8. Nov 12, 2024Reported quarterly or annual results71

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

238 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 75 major events, 110 insider forms, 10 large holders, 22 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 2, 20264 EDGAR
  3. Oct 2, 20264 EDGAR
  4. Oct 2, 20264 EDGAR
  5. Oct 2, 20264 EDGAR
  6. Oct 2, 20264 EDGAR
  7. Sep 25, 202610-K EDGAR
  8. Sep 25, 20268-K EDGAR
  9. Sep 8, 20264/A EDGAR
  10. Sep 8, 20264/A EDGAR
  11. Sep 8, 20264/A FORM 4 EDGAR
  12. Sep 8, 20264/A FORM 4 EDGAR
  13. Sep 8, 20264/A FORM 4 EDGAR
  14. Sep 8, 20264/A FORM 4 EDGAR
  15. Sep 8, 20264/A FORM 4 EDGAR
  16. Sep 1, 20264 EDGAR
  17. Aug 19, 20268-K EDGAR
  18. Aug 19, 2026424B5 EDGAR
  19. Aug 19, 2026424B5 EDGAR
  20. Aug 6, 202610-Q/A EDGAR

The 238 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

46 open-market trades by officers, directors and large owners since October 2021: 45 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 3, 2025Leonard Braden Michael10% ownerSale229,576$7.08$1.6MForm 4
May 29, 2024Becker James FrankDirectorBuy1,100$9.82$10.8KForm 4
May 28, 2024Becker James FrankDirectorBuy934$9.50$8.9KForm 4
May 21, 2024Wilkinson Thomas WileyDirectorBuy1,109$9.50$10.5KForm 4
Mar 15, 2024MCFARLAND ROBERT NDirectorBuy1,185$8.50$10.1KForm 4
Mar 15, 2024Russler Daniel T JrDirectorBuy387$8.42$3.3KForm 4
Mar 15, 2024Becker James FrankDirectorBuy649$8.25$5.4KForm 4
Mar 13, 2024Becker James FrankDirectorBuy839$8.16$6.8KForm 4
Mar 13, 2024Wilkinson Thomas WileyDirectorBuy1,300$8.28$10.8KForm 4
Mar 12, 2024Russler Daniel T JrDirectorBuy500$8.29$4.1KForm 4
Mar 12, 2024Becker James FrankDirectorBuy958$8.14$7.8KForm 4
Dec 29, 2023MCFARLAND ROBERT NDirectorBuy21$8.34$175Form 4
Dec 27, 2023MCFARLAND ROBERT NDirectorBuy1,200$8.19$9.8KForm 4
Dec 11, 2023Russler Daniel T JrDirectorBuy650$7.65$5.0KForm 4
Nov 28, 2023Hinojosa JaimeCFOBuy1,000$8.19$8.2KForm 4
Nov 28, 2023Becker James FrankDirectorBuy490$8.13$4.0KForm 4
Nov 22, 2023Becker James FrankDirectorBuy1,100$7.47$8.2KForm 4
Nov 20, 2023MCFARLAND ROBERT NDirectorBuy1,290$7.80$10.1KForm 4
Nov 17, 2023MCFARLAND ROBERT NDirectorBuy54$7.50$405Form 4
Nov 17, 2023Becker James FrankDirectorBuy1,361$7.66$10.4KForm 4

All 46 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Thomas B. Pickens III$472.5K$954.9K76
2025Jennifer Canas$206.0K$254.4K76
2025Jaime Hinojosa$131.0K$197.4K76
2024Chief Executive Officer$450.0K$1.3M76
2024Chief Financial Officer$315.0K$640.0K76

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Jane Street Group, LLC54,799$597.6K0.0%New
Vanguard Capital Management LLC22,356$243.8K0.0%+13,151
BlackRock, Inc.20,188$220.2K0.0%No change
Geode Capital Management, LLC15,533$169.4K0.0%−3,814
J. Safra Sarasin Holding AG27,300$140.0K0.0%No change
State Street Corp11,068$120.7K0.0%New
SCS Capital Management LLC11,000$120.0K0.0%−761
Vanguard Fiduciary Trust Co7,956$86.8K0.0%+3,617
Jones Financial Companies Lllp886$8.2K0.0%New
Tower Research Capital LLC (TRC)667$7.3K0.0%−1,593
Morgan Stanley77$8400.0%New
UBS Group AG64$6980.0%−136
Federation des caisses Desjardins du Quebec23$2510.0%No change
Wells Fargo & Company/mn20$2180.0%No change
Harbour Investments, Inc.11$1200.0%+3
SBI Securities Co., Ltd.10$1090.0%−3
Caitong International Asset Management Co., Ltd6$650.0%−4,031

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Astrotech Corporation is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARASTROTECH Corp2
  • CIK0001001907
  • Employer ID (EIN)91-127373719
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company19
  • Incorporated inDelaware19
  • Fiscal year endsJune 302
  • Industry code (SIC)3826 Laboratory Analytical Instruments2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address2105 Donley Dr. Suite 100, Austin, TX 787582
  • Mailing address2028 E. Ben White Blvd., Suite 240-9530, Austin, TX 787412
  • Phone51248595302
  • Shares outstanding2,009,050 shares as of Sep 23, 202619
  • Public float$5.3M as of Dec 31, 202519
  • AuditorRBSM LLP, Houston, Texas PCAOB ID 587; no auditor attestation of internal control over financial reporting19
  • On EDGAR sinceFeb 8, 19962
  • Filings1,105 in all: 8-K (329), 4 (268), 10-Q (91), SC 13G/A (68), 3 (41), DEF 14A (32), 10-K (30), SC 13G (30)2
    All 56 form types

    DEFA14A (17), UPLOAD (15), 4/A (13), 424B5 (13), CORRESP (13), SC 13D/A (13), 10-K/A (12), PRE 14A (12), SC 13D (8), SC TO-I/A (8), 10-Q/A (7), S-8 (7), 8-A12B/A (6), EFFECT (6), S-3 (6), 8-A12B (5), 424B3 (4), 425 (4), 8-K/A (4), FWP (3), NT 10-K (3), 40-APP (2), 40-APP/A (2), APP WD (2), D (2), POS AM (2), PRER14A (2), S-1/A (2), S-3/A (2), S-4/A (2), SC TO-I (2), 10-K405 (1), 10-K405/A (1), 424B4 (1), 5 (1), 8-A12G (1), 8-A12G/A (1), APP WDG (1), DEFM14A (1), DEFR14A (1), PREM14A (1), S-1 (1), S-1MEF (1), S-4 (1), S-8 POS (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Sep 25, 2026
    Quarterly report (10-Q) May 13, 2026
    Proxy statement (DEF 14A) Oct 28, 2025
    Latest 8-K (8-K) Sep 25, 2026

Securities registered for trading

ClassSymbolExchange
Common StockASTCNasdaq

From the cover page of the 10-K filed Sep 25, 2026 (Section 12(b) of the Exchange Act).19

Risk factors and legal proceedings

The risks Astrotech Corporation names in Item 1A of its 10-K filed Sep 25, 2026: 53 risks under these headings, as written.19

  • Risks Related to Our Business and Industry
  • We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future.
  • Our business units are in the development stage. They have earned limited revenues and it is uncertain whether they will earn any revenues in the future or whether any of them will ultimately be profitable.
  • We may need to raise additional capital to fund the operations of our business units and commercialize our products.
  • We may not be able to obtain patents, other intellectual property protection or licenses for the technologies contained in the products we develop.
  • Third parties have infringed on our intellectual property rights, and may claim in the future that we are infringing on their intellectual property rights, and we could suffer significant litigation or licensing expenses or be prevented from selling products.
  • We may not be able to successfully develop the BreathTest-1000 or any other new products or services.
  • Our sales and operations in international markets expose us to operational, financial and regulatory risks.
  • Our business, financial condition and results of operations may be adversely impacted by the effects of inflation.
  • We generate substantial revenue from a limited number of customers and the loss of any such customer may harm our business, results of operations and financial results.
  • Our success depends significantly on the establishment and maintenance of successful relationships with our customers.
  • Third parties may claim we are infringing their intellectual property rights, and we could suffer significant litigation or licensing expenses or be prevented from selling products.
The other 42 risks
  • Our ongoing success is dependent upon the continued availability of certain key employees.
  • Our operating results may be adversely affected by increased competition.
  • Our facilities located in Austin are susceptible to damage caused by hurricanes or other natural disasters.
  • If we are unable to anticipate technological advances and customer requirements in the commercial and governmental markets, our business and financial condition may be adversely affected.
  • We incur substantial upfront, non-reimbursable costs in preparing proposals to bid on contracts or to receive research and development grants that we may not be awarded.
  • A failure of a key information technology system, process, or site could have a material adverse impact on our ability to conduct business.
  • Our manufacturing operations are mostly dependent upon third party suppliers, including single source suppliers, making us vulnerable to external factors such as supply shortages and price fluctuations, which could harm our business.
  • Repair or replacement costs due to warranties we provide on our products could have a material adverse effect on our business, financial condition and results of operations.
  • Risks Related to our Strategic Initiatives
  • We intend to explore expanding our business into the Lunar Initiatives and we may not be able to successfully transition our business and may not realize the anticipated synergies and benefits of such proposed transition.
  • The development and maintenance of the technologies and infrastructure necessary to support our new Lunar Initiatives will require significant capital expenditures, and if we are unable to generate sufficient cash flow from operations or obtain additional financing on acceptable terms, our business, financial condition, results of operations, and future prospects could be materially and adversely affected.
  • We are substantially dependent on the outcome of government solicitations and awards, including the Appendix A Program and the CLPS2 Program, and there can be no assurance that we will submit a proposal or be selected for any contract, award or funding.
  • Many of our Lunar Initiatives involve significant technical complexity, unproven technologies, or technologies that do not exist or may require significant advancement, and such Lunar Initiatives may not achieve commercial viability.
  • Our future revenue and operating results depend upon our ability to develop new technologies and respond to changes in customer demands and industry standards in highly competitive markets, and if we are unable to do so, our business, financial condition, results of operations, and future prospects may be materially and adversely affected.
  • The commercial lunar market is undeveloped and uncertain, and there may be insufficient demand for the products and services we intend to develop
  • We expect to face significant competition from well-capitalized commercial entities and government-sponsored programs in the markets we intend to enter, and if we are unable to compete effectively, our business, financial condition and results of operations could be harmed.
  • Our activities to evaluate and pursue strategic alternatives may not be successful, including the announcement and pendency of the proposed sale of 1st Detect, and may present certain risks to our ongoing business and operations.
  • Legal and Regulatory Risks
  • Our products and operations are subject to extensive governmental regulation, and failure to comply with applicable requirements could cause our business to suffer.
  • Failure to obtain clearance or authorization for the BreathTest-1000, or other delays in the development of the BreathTest-1000, would adversely affect our ability to grow our business.
  • We and our suppliers may not meet regulatory quality standards applicable to our device-manufacturing processes, which could have an adverse effect on our business, financial condition, and results of operations.
  • If the BreathTest-1000 or any other device candidates are cleared for commercialization in the United States via the 510(k) process, product modifications may require new 510(k) clearances, de novo submissions, or pre‑market approvals, or may require us to cease marketing or recall the modified products until clearances are obtained.
  • Once our BreathTest-1000 or any other device candidate we may develop in the future, if any, is cleared or approved by FDA for marketing in the United States, if ever, we may be liable if the FDA or other U.S. enforcement agencies determine we have engaged in the off‑label promotion of such products or have disseminated false or misleading labeling or promotional materials.
  • Even if we obtain FDA clearance or approval for BreathTest-1000 or any other medical device product, our products will remain subject to regulatory scrutiny.
  • Legislative or regulatory healthcare reforms may adversely affect our business and our ability to obtain regulatory clearance or approval for, and successfully commercialize, our products.
  • Disruptions at FDA and other government agencies, such as those that may be caused by funding shortages, could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.
  • Our AgLAB business’ growth is highly dependent on the U.S. hemp and cannabis market. New regulations causing licensing shortages and future regulations may create other limitations that decrease the demand for our products. General regulations at state and federal in the future may adversely impact our business.
  • As the possession and use of marijuana is illegal under the CSA, it is possible that our manufacture and sale of equipment that is used to cultivate marijuana or marijuana products may be deemed to be aiding and abetting illegal activities.
  • We may become subject to FDA or ATF regulation with respect to our AgLab business.
  • The hemp and cannabis industry could face strong opposition from other industries.
  • There may be difficulty enforcing certain of our commercial agreements and contracts.
  • A drop in the retail price of hemp and cannabis products may negatively impact our business.
  • We may be subject to constraints on and differences in marketing our products under varying state laws.
  • We are subject to differing tax rates in several jurisdictions in which we operate, which may adversely affect our business, financial condition, results of operations and prospects.
  • Changes in U.S. trade policy, including changes to existing trade agreements and any resulting changes in international trade relations, may have a material adverse effect on us and our export compliance as it relates to our international customers.
  • Risks Related to Ownership of Our Common Stock
  • Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future, and as a result, investors in our common stock could incur substantial losses.
  • We can sell additional shares of common stock without consulting shareholders and without offering shares to existing shareholders, which would result in dilution of shareholders’ interests in the Company and could depress our stock price.
  • Our Certificate of Incorporation provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any disputes between us and our stockholders, which could limit stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors or officers.
  • A sale of a substantial number of shares of the common stock may cause the price of our common stock to decline.
  • We are a smaller reporting company and, as a result of the reduced disclosure and governance requirements applicable to such companies, our common stock may be less attractive to investors.
  • Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our Common Stock.
  • General Risk Factors
  • Increased cybersecurity requirements, vulnerabilities, threats, and more sophisticated and targeted computer crime could pose a risk to our systems, networks, products, services, and data.
  • Increased costs associated with corporate governance compliance may significantly impact our results of operations.
  • Our insurance coverage may be inadequate to cover all significant risk exposures.

Legal proceedings

From time to time, the Company is subject to legal and administrative proceedings, settlements, investigations, claims and actions. The Company’s assessment of the likely outcome of litigation matters is based on its judgment of a number of factors including experience with similar matters, past history, precedents, relevant financial and other evidence and facts specific to the matter. Notwithstanding the uncertainty as to the final outcome, based upon the information currently available, management does not believe any matters, individually or in aggregate, will have a material adverse effect on the Company’s financial position or results of operations.

The opening of Item 3, Legal Proceedings.19

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
    SEC EDGAROther events
  57. 57
  58. 58
    SEC EDGAROther events
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76